Sickle Cell Disease Resources
for Healthcare Providers
Sickle Cell Disease Clinical Program
Agios is committed to developing innovative treatment options that make a meaningful difference in patients’ lives and fundamentally change the way rare and genetically defined diseases are treated. We are leveraging our leadership in PK activation to explore an investigational, oral treatment for sickle cell disease. More information is below.
RISE UP Phase 2/3 Trial
Learn more about our seamless Phase 2/3 trial for sickle cell disease.
“Cheat Codes” A Sickle Cell Podcast
Cheat Codes: A Sickle Cell Podcast is intended for patients, caregivers, providers and the greater community of people who are impacted by sickle cell disease. Each episode strives to provide listeners with critical education, the latest scientific updates and voices from the sickle cell disease community. The podcast is sponsored by Agios Pharmaceuticals, Inc. The program is intended for informational and educational purposes only and is not intended as medical advice. Host and guests featured in each episode have been compensated for their time.
Pyruvate kinase (PK) deficiency is a rare, hereditary, chronic hemolytic anemia caused by mutations in the PKLR gene encoding the enzyme pyruvate kinase, which is critical for maintaining red blood cell (RBC) energy levels and normal RBC life span. Defects in pyruvate kinase lead to premature destruction of erythrocytes which manifest clinically as anemia and serious complications including gallstones, pulmonary hypertension, thrombosis, osteopenia, osteoporosis, and iron overload. Currently, Agios is studying the long-term safety and efficacy of PK activation in adults with PK deficiency and has expanded the clinical trial program to study PK activation in pediatric patients with PK deficiency from 1-17 years of age.
Thalassemia is a diverse group of genetic disorders with a worldwide distribution that are characterized by reduced or absent production of hemoglobin. Imbalanced globin chain production that occurs in thalassemic red blood cells leads to ineffective erythropoiesis, hemolysis, and dysregulated iron homeostasis, resulting in the development of anemia and other clinical complications. Although important advancements in the management of thalassemia have been made over the last few decades, significant unmet needs remain that are not addressed by current approaches. Agios is studying how PK activation could potentially benefit people across the full range of thalassemia types, including both α- and β-thalassemia. PK activation increases adenosine triphosphate (ATP) and enhances the energy metabolism of the red blood cell (RBC), which may lead to improved membrane integrity and RBC health. Currently, Agios is studying PK activation in adults with non-transfusion-dependent and transfusion-dependent thalassemia in ongoing clinical trials to assess effects on both anemia and transfusion burden.
For medical information queries, please contact us at the phone numbers or email addresses below.
Report an adverse event or product complaint anytime.
This site is intended for healthcare professionals; all materials available are for scientific informational purposes only.
Resources available may include educational and information materials relating to Agios’ clinical pipeline, investigational products, therapeutic areas of interest, approved medicines, congress materials, and publications. This site may include information that has not been approved by the US Food and Drug Administration. There is no guarantee that investigational products will receive health authority approvals or become commercially available in any country for the uses under investigation. For approved product full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to approved product labeling.